๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

High-dose midazolam therapy for refractory status epilepticus in children

โœ Scribed by Gavin Morrison; Elizabeth Gibbons; William Patrick Whitehouse


Publisher
Springer
Year
2006
Tongue
English
Weight
298 KB
Volume
32
Category
Article
ISSN
1432-1238

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Orofacial automatisms induced by acute w
โœ David Epstein; Marc Difazio ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 113 KB

## Abstract Nonconvulsive Status Epilepticus (NCSE) is not uncommon in children, and can be challenging to diagnose and treat. Etiologies vary widely and include infection, trauma and acute withdrawal from medications such as anticonvulsants. We report a child who experienced orofacial dyskinesias

FLAG (fludarabine, high-dose cytarabine,
โœ McCarthy, A.J.; Pitcher, L.A.; Hann, I.M.; Oakhill, A. ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 63 KB ๐Ÿ‘ 2 views

Background. The treatment of relapsed and refractory leukemia in children remains a challenge. The morbidity of further chemotherapy is considerable, as most patients have already been exposed to intensive multiagent chemotherapy. The FLAG (fludarabine, high-dose cytarabine, and G-CSF) regimen is as

High doses of gamma globulin and methylp
โœ T. Hara; S. Miyazaki; N. Yoshida; N. Goya ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› Springer ๐ŸŒ English โš– 331 KB

In four children with chronic idiopathic thrombocytopenic purpura (ITP), high doses of gamma globulin or methylprednisolone were effective in increasing platelet counts transiently, yet there was no quantitative relationship between the platelet responses to these two therapies. This finding suggest

Letter to the Editor:FLAG (fludarabine,
โœ Sarper, Nazan; Yalman, Nevin ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 41 KB ๐Ÿ‘ 2 views

## FLAG (Fludarabine, High-Dose Cytarabine and G-CSF) for Refractory and High-Risk Relapsed Acute Leukemia in Children We have read with interest the report about FLAG therapy in childhood acute leukemia by McCarthy et al. [1]. We want to add our experience with IDA-FLAG in poor-risk childhood leuk